Citigroup, whose investment bank is run by ex-JPMorgan banker Vis Raghavan, has taken the biggest hit to its share of deals ...

Merck & Co. is buying the developer of an experimental antiviral drug designed to prevent the flu, as the drugmaker aims to ...

In a statement, Cidara Therapeutics, Inc. (NASDAQ:CDTX) said that it entered into a definitive agreement with Merck, under ...

Major stock indexes finished mixed Friday, with the Dow Jones Industrial Average declining for a second straight session but ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

US stocks declined on Friday (November 14), extending losses after Wall Street recorded its worst session in over a month.

Key Takeaways Merck agreed to pay $9.2 billion to purchase Cidara Therapeutics, looking to cash in on the firm's experimental flu treatment.The $221.50 per share offer is more than twice Cidara's ...

Major U.S. equities indexes were mixed Friday afternoon, following a sharp decline Thursday fueled by a selloff of tech stocks.

Merck & Co. agreed to acquire Cidara Therapeutics Inc., a biotech company developing a flu treatment, as part of its ongoing ...

Cidara Therapeutics, Inc. surges to $217 on a bid by Merck & Co., Inc. valuing shares at $221.50. Learn more about CDTX stock ...

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes ...

Merck announced the $9.2 billion deal with Cidara on Friday, sending Cidara's stock (CDTX) soaring 106% in recent morning trading, enough to make it the biggest gainer on the major U.S. exchanges. The ...